Dupilumab Offers Benefits in Bullous Pemphigoid Management
A clinical trial has shown that dupilumab, a monoclonal antibody targeting IL-4 and IL-13, may offer benefits to patients in managing bullous pemphigoid, a rare autoimmune blistering disease.